Patients' choice on axillary lymph node dissection following sentinel lymph node micrometastasis - First Report on prospective use of a nomogram in very low risk patients

G. Cserni, Istvánné Bezsenyi, László Markó

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The optimal locoregional treatment of patients diagnosed with sentinel node (SN) micrometastasis is controversial. A previously reported and validated nomogram was used to calculate the risk of non-SN metastasis in patients with SN micrometastasis over a period of 2 years. Patients were given detailed information about the risk, consequences and treatment options of non-SN involvement, the risk and potential complications of unnecessary completion axillary lymph node dissection (ALND), the imperfectness of the nomogram, and other factors that may influence their selection of further treatment. They also received a questionnaire to monitor factors influencing their decisions. Of the 25 patients participating in the study, 10 have opted for ALND. The only factor that seemed to influence their choice was fear from disease recurrence. Giving detailed information to SN micrometastatic patients is a patient-centered alternative to current recommendations on performing ALND in all such patients or omitting ALND in all of them.

Original languageEnglish
Pages (from-to)211-216
Number of pages6
JournalPathology and Oncology Research
Volume19
Issue number2
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Neoplasm Micrometastasis
Nomograms
Lymph Node Excision
Sentinel Lymph Node
Fear
Therapeutics
Neoplasm Metastasis
Recurrence

Keywords

  • Axillary lymph node dissection
  • Micrometastasis
  • Nomogram
  • Non sentinel lymph node
  • Patient's choice
  • Sentinel lymph node

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{0a5d185f4d49437f80c717050d0b0153,
title = "Patients' choice on axillary lymph node dissection following sentinel lymph node micrometastasis - First Report on prospective use of a nomogram in very low risk patients",
abstract = "The optimal locoregional treatment of patients diagnosed with sentinel node (SN) micrometastasis is controversial. A previously reported and validated nomogram was used to calculate the risk of non-SN metastasis in patients with SN micrometastasis over a period of 2 years. Patients were given detailed information about the risk, consequences and treatment options of non-SN involvement, the risk and potential complications of unnecessary completion axillary lymph node dissection (ALND), the imperfectness of the nomogram, and other factors that may influence their selection of further treatment. They also received a questionnaire to monitor factors influencing their decisions. Of the 25 patients participating in the study, 10 have opted for ALND. The only factor that seemed to influence their choice was fear from disease recurrence. Giving detailed information to SN micrometastatic patients is a patient-centered alternative to current recommendations on performing ALND in all such patients or omitting ALND in all of them.",
keywords = "Axillary lymph node dissection, Micrometastasis, Nomogram, Non sentinel lymph node, Patient's choice, Sentinel lymph node",
author = "G. Cserni and Istv{\'a}nn{\'e} Bezsenyi and L{\'a}szl{\'o} Mark{\'o}",
year = "2013",
month = "4",
doi = "10.1007/s12253-012-9571-3",
language = "English",
volume = "19",
pages = "211--216",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Patients' choice on axillary lymph node dissection following sentinel lymph node micrometastasis - First Report on prospective use of a nomogram in very low risk patients

AU - Cserni, G.

AU - Bezsenyi, Istvánné

AU - Markó, László

PY - 2013/4

Y1 - 2013/4

N2 - The optimal locoregional treatment of patients diagnosed with sentinel node (SN) micrometastasis is controversial. A previously reported and validated nomogram was used to calculate the risk of non-SN metastasis in patients with SN micrometastasis over a period of 2 years. Patients were given detailed information about the risk, consequences and treatment options of non-SN involvement, the risk and potential complications of unnecessary completion axillary lymph node dissection (ALND), the imperfectness of the nomogram, and other factors that may influence their selection of further treatment. They also received a questionnaire to monitor factors influencing their decisions. Of the 25 patients participating in the study, 10 have opted for ALND. The only factor that seemed to influence their choice was fear from disease recurrence. Giving detailed information to SN micrometastatic patients is a patient-centered alternative to current recommendations on performing ALND in all such patients or omitting ALND in all of them.

AB - The optimal locoregional treatment of patients diagnosed with sentinel node (SN) micrometastasis is controversial. A previously reported and validated nomogram was used to calculate the risk of non-SN metastasis in patients with SN micrometastasis over a period of 2 years. Patients were given detailed information about the risk, consequences and treatment options of non-SN involvement, the risk and potential complications of unnecessary completion axillary lymph node dissection (ALND), the imperfectness of the nomogram, and other factors that may influence their selection of further treatment. They also received a questionnaire to monitor factors influencing their decisions. Of the 25 patients participating in the study, 10 have opted for ALND. The only factor that seemed to influence their choice was fear from disease recurrence. Giving detailed information to SN micrometastatic patients is a patient-centered alternative to current recommendations on performing ALND in all such patients or omitting ALND in all of them.

KW - Axillary lymph node dissection

KW - Micrometastasis

KW - Nomogram

KW - Non sentinel lymph node

KW - Patient's choice

KW - Sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=84879057599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879057599&partnerID=8YFLogxK

U2 - 10.1007/s12253-012-9571-3

DO - 10.1007/s12253-012-9571-3

M3 - Article

VL - 19

SP - 211

EP - 216

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -